Aspirin Attenuates Angiotensin II‐induced Cardiomyocyte Hypertrophy by Inhibiting the Ca2+/Calcineurin‐NFAT Signaling Pathway
Authors:
- 8 January 2016
- journal article
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 34 (1) , 21-29
Abstract
Summary: Introduction: In this study, we examined whether aspirin could inhibit cardiac hypertrophy.Methods: We utilized cultured neonatal mouse cardiomyocytes and mice for the study and subjected to cardiomyocyte immunochemistry, qRT‐PCR, and immunoblotting analysis. The cardiac function was measured using M‐mode echocardiography.Results: Ten μM aspirin significantly inhibited Ang II‐induced increase in cardiomyocyte size, the mRNA, and protein levels of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and β‐myosin heavy chain (β‐MHC) (P < 0.05). Meantime, consistent with the result in vitro, the increase in HW/BW ratio, the mRNA, and protein levels of ANP, BNP, and β‐MHC could be reduced by aspirin in vivo (P < 0.05). Analysis of cardiac function revealed that mouse hearts treated with Ang II displayed thickening of the ventricular walls, left ventricular end‐diastolic dimensions, and left ventricular end‐systolic dimensions were significantly decreased (P < 0.05), whereas interventricular septal thickness at end‐diastole, interventricular septal thickness at end‐systole, posterior wall thickness in diastole, and posterior wall thickness in systole were markedly increased (P < 0.05), which could be reversed by aspirin (P < 0.05). Moreover, aspirin blunted the increase inCa2+ and inhibited the calcineurin activity and NFAT dephosphorylation caused by Ang II (P < 0.05).Conclusions: Aspirin inhibited cardiac hypertrophy in vitro and in vivo through inhibition of the Ca2+/calcineurin–NFAT signaling pathway. Therefore, these findings suggested that aspirin might become a therapeutic option to reduce cardiac hypertrophy.Keywords
This publication has 29 references indexed in Scilit:
- Inhibition of farnesyl pyrophosphate synthase attenuates angiotensin II-induced cardiac hypertrophy and fibrosis in vivoThe International Journal of Biochemistry & Cell Biology, 2013
- Angiotensin-Converting Enzyme 2 Over-Expression in the Central Nervous System Reduces Angiotensin-II-Mediated Cardiac HypertrophyPLOS ONE, 2012
- Modulation of human embryonic stem cell-derived cardiomyocyte growth: A testbed for studying human cardiac hypertrophy?Journal of Molecular and Cellular Cardiology, 2011
- Adrenomedullin Gene Delivery is Cardio-protective in a Model of Chronic Nitric Oxide Deficiency Combining Pressure Overload, Oxidative Stress and Cardiomyocyte HypertrophyCellular Physiology and Biochemistry, 2010
- CaMKII Negatively Regulates Calcineurin–NFAT Signaling in Cardiac MyocytesCirculation Research, 2009
- Role of activated CaMKII in abnormal calcium homeostasis and INa remodeling after myocardial infarction: Insights from mathematical modelingJournal of Molecular and Cellular Cardiology, 2008
- Atorvastatin inhibits GSK-3β phosphorylation by cardiac hypertrophic stimuliBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2008
- Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in miceJournal of Molecular and Cellular Cardiology, 2007
- Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-κB activationBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2005
- Portective Action of Angiotensin Converting Enzyme Inhibitors on Cardiac Hypertrophy in the Aortic-Banded Rat.Japanese Heart Journal, 1999